Trial Profile
A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination With Doxorubicin vs. Doxorubicin Alone in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Evofosfamide (Primary) ; Doxorubicin
- Indications Haemangiosarcoma; Kaposi's sarcoma; Leiomyosarcoma; Liposarcoma; Nerve sheath neoplasms; Rhabdomyosarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Registrational; Therapeutic Use
- Sponsors Threshold Pharmaceuticals
- 28 Jan 2023 This trial has been discontinued in Denmark (End Date: 10 May 2016) and in Poland according to European Clinical Trials Database record.
- 09 Jan 2023 Results of post-hoc analysis assessing mpact of administration mode on adverse events (AEs) and efficacy , published in the Clinical Cancer Research.
- 08 Jun 2021 Data (n=303) were used for a computational analysis from this trial ; radiomics features were extracted from lung metastases patients presented at the 57th Annual Meeting of the American Society of Clinical Oncology